<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890939</url>
  </required_header>
  <id_info>
    <org_study_id>ASV0000001</org_study_id>
    <nct_id>NCT03890939</nct_id>
  </id_info>
  <brief_title>Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability</brief_title>
  <official_title>Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a condition where the upper airway
      partially collapses and closes. This can lead to sleep problems including low oxygen levels,
      poor sleep, elevated carbon dioxide levels in the blood, and activation of the sympathetic
      nervous system. Results from having disrupted sleep may be excessive daytime sleepiness along
      with behavioral, functional, cardiovascular and cognitive dysfunction. Continuous Positive
      Airway Pressure (CPAP) is the most effective treatment for OSAHS. CPAP stabilizes the airway
      and prevents instability and collapse. Other forms of positive airway pressure that are
      approved for the treatment of OSAHS include automatically adjusting CPAP, Bi-level Positive
      Airway Pressure (BiPAP), and automatically adjusting BiPAP. Automatically adjusting CPAP
      (Auto CPAP) evaluates the airflow pattern and adjusts pressure to optimize airflow. AutoSV
      (Auto Servo Ventilation) is a mode of positive airway pressure used to treat obstructive and
      complex central sleep apnea.

      In the prior study, the investigators found that the Auto S7 device led to more positive
      ventilation outcomes. Specifically, there was prolongation of QTc interval (the calculated
      time from the Q wave to the end of the T wave) and a tendency for greater premature
      ventricular contractions. The mechanistic basis for this could be attributable to excessive
      ventilation and related pro-arrhythmic effects of hypocapnia, though the investigators had
      not performed measures (partial pressure of CO2 (PaCO2) to detect this.

      In the current study, the investigators would like to investigate the hypothesis that the S7
      device leads to lower PaCO2 levels than other devices, and whether these effects are
      augmented in individuals with complex sleep apnea in the setting of systolic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a condition characterized by
      intermittent partial collapse and closure of the upper airway (UA). This leads to sleep
      fragmentation, oxygen desaturation, hypercarbia, and activation of the sympathetic nervous
      system. OSAHS is also associated with excessive daytime sleepiness, as well as other
      behavioral, functional, cardiovascular and cognitive dysfunction.

      Continuous Positive Airway Pressure (CPAP) is the most effective treatment for the OSAHS.
      CPAP stabilizes the airway and prevents instability and collapse. With a stable airway,
      breathing continues in a normal manner, gas exchange is improved, and there is no disruption
      of sleep related to disturbed breathing.

      CPAP is applied to the upper airway via a mask that covers the nose or the nose and mouth and
      reduces/eliminates sleep disordered breathing. The period of maximum susceptibility to airway
      collapse is at the end of exhalation and during early inhalation. During inhalation, negative
      pressures are generated in the airway by the normal process of ventilation (increase of
      thoracic volume and reduction of intra-thoracic pressure). The constant pressure of CPAP
      supports the airway throughout the ventilatory cycle.

      In the sleep laboratory, titration of positive airway pressure is performed to determine
      effective CPAP pressures. During the procedure, the patient is instrumented for full
      polysomnography (PSG). Therapy is applied and pressure is adjusted during the course of the
      night to stabilize the upper airway and the breathing pattern. With conventional CPAP, a
      single pressure level is applied to the airway. While adequate for a majority of patients
      with obstructive sleep apnea, this static prescription will present challenges in certain
      patients and conditions.

      Other forms of positive airway pressure that are approved for the treatment of OSAHS include
      automatically adjusting CPAP (Auto CPAP), Bi-level Positive Airway Pressure (BiPAP), and
      automatically adjusting BiPAP. Auto CPAP evaluates the airflow pattern and adjusts pressure
      to optimize airflow. Auto CPAP accommodates patients presenting with highly variable pressure
      requirements (e.g., sleep stage or body position dependent sleep apnea). The automatic
      adjustment can be used in patients for whom in-laboratory therapy titration is either delayed
      or impossible.

      The REMStar Auto algorithm is proactive and flow-based. It evaluates the inspiratory flow and
      determines impending or actual flow limitation. This occurs in concert with a program of
      pressure adjustments designed to evaluate the pressure at which the airway is susceptible to
      collapse and maintains pressures slightly above the critical pressure. The patient is
      protected from &quot;break-through&quot; events with a full complement of intelligent responses to
      airflow events and snoring.

      BiPAP therapy is another alternative. With BiPAP therapy, the patient's breathing pattern is
      monitored to identify the inspiratory and expiratory phases. Pressure is increased during
      inhalation and decreased during exhalation. The expiratory pressure (EPAP) is adjusted to
      prevent airway collapse and the inspiratory pressure (IPAP) is adjusted to prevent airflow
      limitation, hypopnea, snoring or arterial desaturation not associated with complete airway
      obstruction. BiPAP therapy differs from CPAP therapy, in that in addition to stabilizing the
      airway, inspiratory effort is assisted by the difference between the inspiratory and
      expiratory pressure.

      Patients with OSAHS may be prescribed BiPAP therapy if CPAP therapy is not tolerated. BiPAP
      therapy may also be prescribed for patients with other respiratory disorders or for patients
      with both sleep and respiratory-related dysfunction.

      Patients experiencing reduced ventilation from lung disease, neuromuscular disorders, or
      problems with the control of the breathing can experience nocturnal hypoventilation that is
      worse during sleep than it is during wakefulness. These patients are typically more complex
      and require more extensive evaluation and follow-up than patients suffering only from OSAHS.
      Patients may also be more vulnerable to loss or interruptions in treatment and often require
      more advanced modes and features such as alarms and timed back-up breaths.

      OSAHS patients may respond to increases in CPAP or BiPAP therapy by demonstrating a shift in
      the nature of the apnea from obstructive to central. In these cases, patients may not receive
      adequate treatment with CPAP since lower pressure levels do not manage the instability of the
      airway leaving residual airway obstruction, while higher pressure levels are associated with
      CPAP emergent events. This condition is referred to as CPAP Emergent Complex Apnea.

      Auto SV (Auto Servo Ventilation) is a mode of positive airway pressure used to treat
      obstructive and complex central sleep apnea. Its main features include:

        -  Normalization of ventilation by automatically adjusting IPAP pressure to achieve a
           target ventilation.

        -  Provision of timed, back-up breaths during central apneas. The optimal back-up rate is
           automatically determined by the device based on the patient's breathing.

        -  Automatic control of EPAP pressure to treat obstructive events.

      Several manufacturers produce these types of devices. The algorithms used to determine the
      IPAP, EPAP and minimum respiratory rate are different. The largest number of these devices
      currently in use are the BiPAP AutoSV Advanced System One (Philips Respironics, Murrysville
      PA), Dreamstation BiPAP AutoSV and the VPAP (variable positive airway pressure) Adapt S7
      (ResMed Corp., San Diego CA).

      Adaptive Servo Ventilation (ASV) is a mode of positive airway pressure used to treat central
      sleep apnea and complex sleep apnea. The main features of the Auto SV mode include;
      normalization of ventilation by automatically adjusting IPAP to achieve and stabilize a
      target ventilation; provision of timed, back-up breaths during central apneas wherein the
      optimal back-up rate is automatically determined by the device based on the patient's
      breathing; and automatic control of EPAP to treat obstructive events.

      The older version of the VPAP Adapt (S7) was found to lead to increased risk for all-cause
      mortality when compared to control group that involved medical management in patients with
      heart failure with reduced ejection fraction and predominantly central sleep apnea in a
      recent study (SERVE-HF). An accompanying editorial by Magalang and Pack suggested that the
      device algorithms may have played a role -- specifically, greater levels of pressure assist
      and associated increase in minute ventilation. This was supported by the measurements of
      minute ventilation delivered by the S7 device in the trial which was found to be greater than
      other servo-ventilation devices. Such increased levels of ventilation could potentially cause
      respiratory alkalosis which, in turn, could lead to QT interval prolongation and cardiac
      arrhythmias. The investigators recently performed a study of patient-ventilator interaction
      in patients with complex sleep apnea and preserved cardiac contractility (left ventricular
      ejection fraction &gt; 45%) in order to determine the performance of various ASV devices on
      respiratory parameters - such as minute ventilation and apnea-hypopnea index. In order to
      facilitate feasibility and promote safety, the investigators avoided performing the study in
      the target population of the SERVE-HF trial, viz., patients with predominant central sleep
      apnea and heart failure with reduced ejection fraction (HFreF). The investigators performed
      the study only on patients with preserved ejection fraction (LVEF &gt; 45%). In the current
      proposal, the investigators propose to perform the study on patients with predominantly
      obstructive sleep apnea and HFreF who need ASV therapy due to PAP-emergent central apneas.

      In the prior study, in order to avoid intolerance to device therapy, the investigators
      preferred study patients who were already adherent in using servo ventilation therapy at
      home. The investigators will do the same in the currently proposed study. In the prior study,
      the investigators found that S7 device led to greater minute ventilation than other devices
      and that such greater levels of minute ventilation was attributable to a greater tidal
      volume, higher respiratory rate, and greater pressure assist. Interestingly, there was
      prolongation of QTc interval and a tendency for greater premature ventricular contractions in
      the same patients during the nights that they were exposed to the S7 device. Although the
      mechanistic basis for this finding is potentially attributable to excessive ventilation and
      related pro-arrhythmic effects of hypocapnia, the investigators had not performed measures of
      partial pressure of CO2 (PaCO2) in this prior study. Specifically, it is unclear whether
      therapy with the S7 device leads to lower PaCO2 levels than other devices and whether such
      effects are augmented in individuals with high loop gain (complex sleep apnea in the setting
      of HFreF).

      Increases in minute ventilation (Ve) during wakefulness causes hypocapnia (respiratory
      alkalosis), which, in turn, could cause hypokalemia. Hypokalemia due to nighttime
      intracellular shifts in potassium ions can prolong QT interval. Conceivably, nighttime
      alkalosis due to excessive ventilation may lead to daytime hypokalemia and QTc prolongation
      through renal loss of potassium at night with consequent effects on QTc prolongation during
      the daytime. The observed QTc prolongation during S7 therapy was small in magnitude (~ 20
      msec), but such effects may be magnified in patients with heart failure who develop metabolic
      alkalosis due to loop diuretics.The investigators did not, however, measure serum potassium
      levels which was a study limitation. In the current proposal, the investigators will
      ascertain the effects of nocturnal ASV therapy on serum potassium levels. Lastly, the
      investigators will explore the inter-individual variability in susceptibility in measured Ve
      or QTc interval.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive three (3) randomized PSG's during which they will receive treatment from the following devices in a randomized manner:
FDA released Philips BiPAP AutoSV Advanced System One
FDA released Philips Dreamstation BiPAP AutoSV
FDA released ResMed S7 VPAP Adapt</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>There will be no masking involved in this study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Minute Ventilation</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>Minute Ventilation is the amount of air the subject moves in one minute. It is a product of the ventilatory rate and tidal volume. Scores are reported in liters per volume, and is collected from the ventilation device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tidal Volume</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>Tidal Volume is the lung volume representing the normal volume of air displaced between normal inhalation and exhalation when extra effort is not applied. Scores are reported in ml/kg, and is collected from the ventilation device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>Respiratory Rate is measured by the number of breaths taken per minute. Scores are reported in breaths per minute, and is collected from the ventilation device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc Intervals</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>QTC intervals are utilized to assess the time it takes for the heart to go from the start of the Q wave to the end of the T wave, and approximates to the time taken from when the cardiac ventricles start to contract when they finish relaxing. Scores are reported in milliseconds, and is collected from the electrocardiogram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acid-Base Status</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>Acid-base status is utilized to determine if subjects have increased/decreased partial carbon dioxide levels (PCO2), or decreased/increased extracellular base excess or actual Bicarbonate levels (HCO3). This is measured through transcutaneous PCO2 monitoring as well as through venipuncture blood collection. Scores are reported in millimoles per liter (mmol/l).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrolyte Status</measure>
    <time_frame>Change from Baseline through Day 4</time_frame>
    <description>Electrolytes Sodium (Na), Potassium (K), and Chlorine (CI) is collected through venipuncture blood collection. Scores are reported in millimoles per liter (mmol/l).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sleep Apnea, Mixed</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>BiPAP AutoSV Advanced System One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dreamstation BiPAP AutoSV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ResMed S7 VPAP Adapt device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPAP AutoSV Advanced System One</intervention_name>
    <description>A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.</description>
    <arm_group_label>BiPAP AutoSV Advanced System One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dreamstation BiPaP AutoSV</intervention_name>
    <description>A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.</description>
    <arm_group_label>Dreamstation BiPAP AutoSV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ResMed S7 VPAP Adapt Device</intervention_name>
    <description>A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.</description>
    <arm_group_label>ResMed S7 VPAP Adapt device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide consent

          -  Currently prescribed servo ventilation therapy at home

          -  At least two weeks of recent adherence and efficacy data from PAP device demonstrating
             adequate use of therapy (at least 4 hours of use per night and use on at least 10 of
             14 nights)

          -  Individuals with complex sleep apnea (obstructive sleep apnea with central apneas) and
             preserved left-ventricular ejection fraction (LVEF &gt; 45%) and/or heart failure with
             preserved ejection fraction (HFrEF) who are currently on ASV therapy.

          -  Individuals with complex sleep apnea (predominantly obstructive sleep apnea with
             central apneas) and reduced left-ventricular ejection fraction (LVEF &lt; 45%) and/or
             heart failure with reduced ejection fraction (HFrEF) who are currently on ASV therapy.

        Exclusion Criteria:

          -  Participants who are acutely ill, medically complicated or who are medically unstable

          -  Participants in whom PAP therapy is otherwise medically contraindicated

          -  Participants who are claustrophobic

          -  Symptomatic (&quot;Symptomatic&quot; defined as hospitalized for heart failure or a change in
             cardiac medications, within the last two months) chronic heart failure (NYHA 2-4) AND
             moderate to severe predominant central sleep apnea

          -  Participants with previously diagnosed respiratory failure or respiratory
             insufficiency and who are known to have elevated arterial carbon dioxide levels while
             awake (PaCO2 â‰¥ 55mmHg).

          -  Participants requiring any kind of oxygen therapy

          -  Participants who have had surgery of the upper airway, nose, sinus, eyes, or middle
             ear within the previous 90 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sairam Parthasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Morton</last_name>
    <phone>(520) 626-8457</phone>
    <email>cjmorton@email.arizona.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Berryhill</last_name>
    <email>smarkows@email.arizona.edu</email>
  </overall_contact_backup>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Apnea, Mixed</keyword>
  <keyword>Sleep Apnea Device</keyword>
  <keyword>BiPap device</keyword>
  <keyword>Sleep Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

